OBJECTIVE: To examine the association between hepatitis C and prevalent cardiovascular disease (CVD) among HIV-infected individuals. DESIGN: A cross-sectional analysis of data from the HIV-Longitudinal Interrelationships of Viruses and Ethanol (HIV-LIVE) cohort, a prospective cohort of HIV-infected individuals with current or past alcohol problems. METHODS: We analysed health questionnaire and laboratory data from 395 HIV-infected individuals (50.1% co-infected with hepatitis C) using logistic regression to estimate the odds ratio (OR) for the prevalence of CVD among those co-infected with hepatitis C and HIV compared with those infected with HIV alone. RESULTS: The prevalence of CVD was higher among those co-infected with hepatitis C compared with those with HIV alone (11.1 versus 2.5%, respectively). After adjusting for age, the OR for the prevalence of CVD was significantly higher among those with hepatitis C co-infection (adjusted OR 4.65, 95% confidence interval 1.70-12.71). The relationship between hepatitis C and CVD persisted when adjusting for age and other sociodemographic characteristics, substance use, and cardiovascular risk factors in separate regression models. CONCLUSION: Co-infection with hepatitis C among a cohort of HIV-infected individuals was associated with a higher age-adjusted odds for the prevalence of CVD. These data suggest that hepatitis C infection may be associated with an increased risk of CVD among those co-infected with HIV.
OBJECTIVE: To examine the association between hepatitis C and prevalent cardiovascular disease (CVD) among HIV-infected individuals. DESIGN: A cross-sectional analysis of data from the HIV-Longitudinal Interrelationships of Viruses and Ethanol (HIV-LIVE) cohort, a prospective cohort of HIV-infected individuals with current or past alcohol problems. METHODS: We analysed health questionnaire and laboratory data from 395 HIV-infected individuals (50.1% co-infected with hepatitis C) using logistic regression to estimate the odds ratio (OR) for the prevalence of CVD among those co-infected with hepatitis C and HIV compared with those infected with HIV alone. RESULTS: The prevalence of CVD was higher among those co-infected with hepatitis C compared with those with HIV alone (11.1 versus 2.5%, respectively). After adjusting for age, the OR for the prevalence of CVD was significantly higher among those with hepatitis C co-infection (adjusted OR 4.65, 95% confidence interval 1.70-12.71). The relationship between hepatitis C and CVD persisted when adjusting for age and other sociodemographic characteristics, substance use, and cardiovascular risk factors in separate regression models. CONCLUSION: Co-infection with hepatitis C among a cohort of HIV-infected individuals was associated with a higher age-adjusted odds for the prevalence of CVD. These data suggest that hepatitis C infection may be associated with an increased risk of CVD among those co-infected with HIV.
Authors: Howard Libman; Richard Saitz; David Nunes; Debbie M Cheng; Jessica M Richardson; John Vidaver; Julie K Alperen; Jeffrey H Samet Journal: Am J Gastroenterol Date: 2006-06-16 Impact factor: 10.864
Authors: Henry Völzke; Christian Schwahn; Birger Wolff; Renate Mentel; Daniel M Robinson; Volker Kleine; Stephan B Felix; Ulrich John Journal: Atherosclerosis Date: 2004-05 Impact factor: 5.162
Authors: Lisa Kakinami; Michael J Adams; Robert C Block; Susan E Cohn; Benedict Maliakkal; Susan G Fisher Journal: AIDS Res Hum Retroviruses Date: 2012-04-10 Impact factor: 2.205
Authors: Daniel Fuster; Debbie M Cheng; Emily K Quinn; David Nunes; Richard Saitz; Jeffrey H Samet; Judith I Tsui Journal: Addiction Date: 2013-10-24 Impact factor: 6.526
Authors: Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Kathleen McGinnis; Lewis H Kuller; Kevin L Kraemer; David Rimland; Matthew B Goetz; Adeel A Butt; Maria C Rodriguez Barradas; Cynthia Gibert; David Leaf; Sheldon T Brown; Jeffrey Samet; Lewis Kazis; Kendall Bryant; Amy C Justice Journal: Circ Cardiovasc Qual Outcomes Date: 2011-06-28
Authors: Jason J Sico; Chung-Chou H Chang; Kaku So-Armah; Amy C Justice; Elaine Hylek; Melissa Skanderson; Kathleen McGinnis; Lewis H Kuller; Kevin L Kraemer; David Rimland; Matthew Bidwell Goetz; Adeel A Butt; Maria C Rodriguez-Barradas; Cynthia Gibert; David Leaf; Sheldon T Brown; Jeffrey Samet; Lewis Kazis; Kendall Bryant; Matthew S Freiberg Journal: Neurology Date: 2015-04-10 Impact factor: 9.910
Authors: Jason Reingold; Christine Wanke; Donald Kotler; Cora Lewis; Russell Tracy; Steven Heymsfield; Phyllis Tien; Peter Bacchetti; Rebecca Scherzer; Carl Grunfeld; Michael Shlipak Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731
Authors: Rebeccah A McKibben; Sabina A Haberlen; Wendy S Post; Todd T Brown; Matthew Budoff; Mallory D Witt; Lawrence A Kingsley; Frank J Palella; Chloe L Thio; Eric C Seaberg Journal: J Infect Dis Date: 2015-07-27 Impact factor: 5.226
Authors: Judith Tsui; Eric Vittinghoff; Kathryn Anastos; Michael Augenbraun; Mary Young; Marek Nowicki; Mardge H Cohen; Marion G Peters; Elizabeth T Golub; Lynda Szczech Journal: Am J Kidney Dis Date: 2009-04-25 Impact factor: 8.860